Literatur

Akute Pankreatitis


- Balthazar EJ: Acute pancreatitis: assessment of severity with clinical and CT evaluation; Radiology 2002; 223(3): 603-13


- Bhasin DK, Rana SS, Rawal P.: Endoscopic retrograde pancreatography in pancreatic trauma: need to break the mental barrier; J Gastroenterol Hepatol 2009; 24(5): 720-8


- Bradley EL III: A Clinically Based Classification System for Acute Pancreatitis; Arch Surg 1993; 128: 586-90

- Brown A, Orav J, Banks PA: Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis; Pancreas 2000; 20: 367-72


- Dellinger EP, Tellado JM, Soto NE: Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study; Ann Surg 2007; 245: 674-83


Götzinger P, Sautner T, Kriwanek S: Surgical Treatment for Severe Acute Pancreatitis: Extent and Surgical Control of Necrosis Determine Outcome; World J Surg 2002; 26(4): 474-8


Himal HS: Role of endoscopic retrograde cholangiopancreatography in early acute biliary pancreatitis; Surg Endosc 1999; 13: 541


Lobo DN, Memon MA, Allison SP, Rowlands BJ: Evolution of nutritional support in acute pancreatitis; Br J Surg 2000; 87: 695-707

Macari M, Finn ME, Bennett GL et al.: Differentiating pancreatic cystic neoplasms from pancreatic pseudocysts at MR imaging: value of perceived internal debris; Radiology 2009; 251(1): 77-84


Schein M, Ivatury R: Intra-abdominal hypertension and the abdominal compartment syndrome; Br J Surg 1998; 85: 1027-8

Singer M, Deutschman CS, Seymour CW et al.: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); JAMA 2016; 315(8): 801-10

Stimac D, Miletić D, Radić M et al.: The role of nonenhanced magnetic resonance imaging in the early assessment of acute pancreatitis; Am J Gastroenterol 2007; 102(5): 997-1004

Struyvenberg MR, Martin CR, Freedman D: Practical guide to exocrine pancreatic insufficiency – Breaking the myths; BMC Medicine 2017; 15: 29

Thomas S, Kayhan A, Lakadamyali H, Oto A: Diffusion MRI of acute pancreatitis and comparison with normal individuals using ADC values; Emerg Radiol 2012; 19(1): 5-9

Uhl W, Buchler M, Malfertheiner P, Isenmann R: Pancreatic necrosis develops within four days after the acute attack; Gastroenterology 1991; 100: 123A


Zaheer A, Singh VK, Qureshi RO et al.: The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines; Abdom Imaging 2013; 38(1): 125-36

---

**Chronische Pankreatitis – Bildgebende Verfahren**


Calvo MM, Bujanda L, Calderón A et al.: Comparison between magnetic resonance cholangiopancreatography and ERCP for evaluation of the pancreatic duct; Am J Gastroenterol 2002; 97(2): 347-53


• Sugiyama M, Haradome H, Atomi Y: Magnetic resonance imaging for diagnosing chronic pancreatitis; J Gastroenterol 2007; 42 Suppl 17: 108-12

• Tamura R, Ishibashi T, Takahashi S: Chronic pancreatitis: MRCP versus ERCP for quantitative caliber measurement and qualitative evaluation; Radiology 2006; 238(3): 920-8

**Chronische Pankreatitis – Interventionelle Therapie**


• Catalano MF, Linder JD, George S et al.: Treatment of symptomatic distal common bile duct stenosis secondary to chronic pancreatitis: comparison of single vs. multiple simultaneous stents; Gastrointest Endosc 2004; 60(6): 945-52


• Devière J, Nageshwar Reddy D, Püspök A et al.: Successful management of benign biliary strictures with fully covered self-expanding metal stents; Gastroenterology 2014; 147(2): 385-95

• Dite P, Ruzicka M, Zboril V, Novotny I: A prospective, randomized trial comparing endoscopic and surgical therapy for chronic pancreatitis; Endoscopy 2003; 35(7): 553-8

• Haapamäki C, Kylänpää L, Udd M et al.: Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitis; Endoscopy 2015; 47(7): 605-10

• Jacobson BC, Baron TH, Adler DG et al.: ASGE guideline: The role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas; Gastrointest Endosc 2005; 61(3): 363-70


• Mangiavillano B, Pagano N, Baron TH et al.: Biliary and pancreatic stenting: Devices and insertion techniques in therapeutic endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography; World J Gastrointest Endosc 2016; 8(3): 143-56


• Rösch T, Dittler HJ: Routine use of transrectal ultrasound rectal carcinoma: results of a prospective multicenter study; Endoscopy 2002; 34: 385–90
Chronische Pankreatitis – Langzeitüberleben


Chronische Pankreatitis – Schmerztherapie


Chronische Pankreatitis – Guidelines


Zystische Tumore des Pankreas – Bildgebende Verfahren

- Morana G, Guarise A: Cystic tumors of the pancreas; Cancer Imaging 2006; 6: 60-71
- Sahani DV, Kadavigere R, Saokar A et al.: Cystic pancreatic lesions: a simple imaging-based classification system for guiding management; Radiographics 2005; 25: 1471-84
- Schima W, Ba-Ssalamah A, Plank C et al.: Pancreas Part II: Tumors; Radiologe 2006; 46: 421-437

Zystische Tumore des Pankreas – Chirurgie

- Adsay V, Mino-Kenudson M, Furukawa T et al.: Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of


- Kallen ME, Naini BV: Intrac ductal Oncolytic Papillary Neoplasms of the Pancreas; Arch Pathol Lab Med 2016; 140(9): 992-6


- Sakorafas GH, Sarr MG. Cystic neoplasms of the pancreas; what a clinician should know; Cancer Treat Rev 2005; 31(7): 507-35

- Sarr MG, Carpenter HA, Prabhakar LP et al.: Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg 2000; 231(2): 205-12


• Warshaw AL, Compton CC, Lewandrowski K et al.: Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients; Ann Surg 1990; 212(4): 432-43; discussion 444

Zystische Tumore des Pankreas – Guidelines


• Tanaka M, Chari S, Adsay V: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas; Pancreatology 2006; 6(1-2): 17-32

Pankreaskarzinom – Bildgebende Verfahren

• Bipat S, Phoa SSKS, van Delden OM et al.: Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic carcinoma; J Comput Assist Tomogr 2005; 29: 438-45


• Grenacher L, Klaus M, Dukic L et al.: Hochauflösende Bildgebung beim Pankreaskarzinom: Prospektiver Vergleich von MRT und 4-Zeilen-Spiral-CT; Fortschr Röntgenstr 2004; 176: 1624-33

• Irie H, Honda H, Kaneko K et al.: Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma; Abdom Imaging 1997; 22: 429-33


• Mallery JS, Centeno BA, Hahn PF et al.: Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity; Gastrointest Endoscopy 2002; 56: 218–24


Pankreaskarzinom – Chirurgie


Buchler MW, Wagner M, Schmied BM et al.: Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy; Arch Surg 2003; 138(12): 1310-4; discussion 1315


Gudjonsson B: Cancer of the pancreas. 50 years of surgery; Cancer 1987; 60(9): 2284-303


Wagner M, Redaelli C, Lietz M et al.: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma; Br J Surg 2004; 91(5): 586-94

White RR, Shah AS and Tyler DS: Pancreatic cancer since Halsted: how far have we come and where are we going?: Ann Surg 2003; 238(6 Suppl): S132-44; discussion S145-7


Pankreaskarzinom – Adjuvante Chemotherapie

Chua YJ and Cunningham D: Adjuvant treatment for resectable pancreatic cancer; J Clin Oncol 2005; 23(20): 4532-7


• Herman JM, Swartz MJ, Hsu CC et al: Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital; J Clin Oncol 2008; 26: 3503-10

• Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection; Arch Surg 1985; 120(8): 899-903


• Regine WF, Winter KA, Abrams RA et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial; JAMA 2008; 299(9): 1019


Pankreaskarzinom – Radio- und/oder Chemotherapie bei lokal fortgeschrittenen Tumoren

- Brasiuniene B, Juozaityte E: The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer; Medicina (Kaunas) 2007; 43(9): 716
- Crane CH, Ellis LM, Abbruzzese JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer; J Clin Oncol 2006; 24(7): 1145-51
- Hammel P, Huguet F, Van Laethem JL et al.: Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4
months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study; J Clin Oncol 31, 2013 (suppl; abstr LBA4003)

• Hammel P, Huguet F, Van Laethem JL et al.: Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial; JAMA 2016; 315(17): 1844-53


• House MG, Yeo CJ, Cameron JL et al.: Predicting resectability of periampullary cancer with three-dimensional computed tomography; J Gastrointest Surg 2004; 8(3): 280-8


• Klaassen DJ, MacIntyre JM, Catton GE et al: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study; J Clin Oncol 1985; 3(3): 373


• Li CP, Chao Y, Chi KH et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study; Int J Radiat Oncol Biol Phys 2003; 57(1): 98


• Sultana A, Smith CT, Cunningham D et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer; J Clin Oncol 2007; 25(18): 2607-15

• Talamonti MS, Small W Jr, Mulcahy MF et al.: A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma; Ann Surg Oncol 2006; 13(2) 150-8


• Varadhachary GR: Current management of borderline-resectable pancreatic cancer; Clin Adv Hematol Oncol 2007; 5(10): 765-7

• Wolff, RA: Initial Results of Preoperative Gemcitabine (GEM)-based Chemoradiation for Resectable Pancreatic Adenocarcinoma; Proc Am Soc Clin Oncol 2002; 21: 130a

• Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer; J Clin Oncol 2004; 22: 2610-6

**Pankreaskarzinom – Palliative Therapie**

• Abou-Alfa GK, Letourneau R, Harker G et al.: A randomized phase III trial of DX- 8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer; Proc Am Soc Clin Oncol 2004; Abstract 4006

• Berk V, Ozdemir N, Ozkan M et al.: XELOX vs. FOLFOX as second line chemotherapy in advanced pancreatic cancer; Hepatogastroenterology 2012; 59(120): 2635-9


• Chiorean EG, Von Hoff DD, Tabernero J et al.: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer; Br J Cancer 2016; 115(2): 188-94


• Gill S, Ko YJ, Cripps C et al.: PANCREOX: A Randomized Phase III Study of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy; J Clin Oncol 2016; Epub ahead of print

• Glimelius B, Hoffman K, Sjoden PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer; Ann Oncol 1996; 7: 593–600

• Herman JM, Swartz MJ, Hsu CC et al.: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital; J Clin Oncol 2008; 26(21): 3503-10


• Kindler HL, Niedzwiecki D, Hollis D et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB); J Clin Oncol 2007; ASCO Annual Meeting Proceedings 25 (18S): 4508

• Louvet C, Hincke A, Labianca R et al.: Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study; J Clin Oncol 2006; ASCO Annual Meeting Proceedings 24 (18S): 4003


• Neuhaus P, Riess H, Post S et al: CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC); J Clin Oncol (ASCO annual meeting proceedings (post-meeting edition) 2008; (vol 26, 20 May Supplement): LBA4504

• Oettle H, Riess H, Stieler JM et al.: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial; J Clin Oncol 2014; 32(23): 2423-9


• Poplin E, Levy DE, J. Berlin J et al.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201); ASCO 2006, Abstract No: LBA4004

• Regine WF, Winter KW, Abrams R et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial; JAMA 2008; 299 (9): 1019–26


• Stocken DD, Büchler MW, Dervenis C et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer; Br J Cancer 2005; 92 (8): 1372–81


• Sultana A, Tudur Smith C, Cunningham D et al.: Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy; Br J Cancer 2007; 96 (8): 1183–90

• Tabernero J, Von Hoff D, Moore M et al.: Phase III trial (MPACT) of weekly nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer: influence of prognostic factors on survival; Ann Oncol 2013; iv11-iv24 (abstr.0-0001)


• Van Heek NT, Kuhlmann KF, Scholten RJ et al.: Hospital volume and mortality after pancreatic resection. A systematic review and an evaluation of intervention in the netheralands; Annals of Surgery 2005; 242: 781-90


• Wang-Gilliam A, Li CP, Bodoky G et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial; Lancet 2016; 387(10018): 545-57

• Wilkowski R, Boeck S, Ostermaier S et al.: Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer—a multi-centre randomised phase II study; Br J Cancer 2009; 101(11): 1853-9
• Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer; J Clin Oncol 2004; 22: 2610-6


Pankresaskarzinom – Leitlinien

• S3-Leitlinie Exokrines Pankresaskarzinom (gültig Okt 2013-Okt 2018)
• ASCO-Guidelines 2016

Neuroendokrine Tumore – Definition, Inzidenz, Klinik, Diagnostik, Chirurgie


• Capurso G, Bettini R, Rinzivillo M et al.: Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review; Neuroendocrinology 2011; 93(4): 223-9

• Falconi M, Eriksson B, Kaltsas G et al.: Consensus guidelines update for the management of functional p-NETs (F-p-NETs) and non-functional p-NETs (NF-p-NETs); Neuroendocrinology 2016; 103(2): 153–71

• Fischer L, Bergmann F, Schimmack S et al.: Outcome of surgery for pancreatic neuroendocrine neoplasms; Br J Surg 2014; 101: 1405-12

• Halfdanarson TR, Rubin J, Farnell MB et al.: Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors; Endocrine-Related Cancer 2008; 15: 409-27

• Hashim YM1, Trinkaus KM, Linehan DC et al.: Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs); Ann Surg 2014; 259(2): 197-203


• Niederle MB, Hackl M, Kaserer K et al.: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters; Endocr Relat Cancer 2010; 17: 909-18

• Niederle MB, Niederle B: Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors: Current Data on a Prospectively Collected, Retrospectively Analyzed Clinical Multicenter Investigation; Oncologist 2011; 16: 602-13

• Rindi G, Klöppel G, Allman H et al.: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system; Virchows Arch 2006; 449: 395-401


• Rosai J.: Pathology and Genetics of Tumors of the Endocrine Organs. In Kleihues P, Sobin L (editors); Lyon 2017: IARC Press


**Neuroendokrine Tumore – Systemische Therapie**


• Cives M, Strosberg J: An update on gastroenteropancreatic neuroendocrine tumors; Oncology 2014; 28(9): 749-58

• Jensen RT, Delle Fave G: Promising Advances in the Treatment of Malignant Pancreatic Endocrine Tumors; NEJM 2011; 364(6): 564-5


• Yao JC, Fazio N, Singh S et al.: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study; Lancet 2016; 387(10022): 968-77

**Neuroendokrine Tumore – Guidelines**

• Pavel M, O’Toole D, Costa F et al: ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site; Neuroendocrinology 2016; 103: 172-85